Design and optimization of novel Tetrahydro-β-carboline-based HDAC inhibitors with potent activities against tumor cell growth and metastasis

被引：0
|
作者：
Fan, Shule [1 ]
Wan, Zeyi [1 ]
Qu, Yuhua [1 ]
Lu, Wenxia [1 ]
Li, Xiangzhi [1 ]
Yang, Feifei [1 ]
Zhang, Hua [1 ]
机构：
[1] Univ Jinan, Sch Biol Sci & Technol, Jinan 250022, Shandong Provin, Peoples R China
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2024年 / 114卷
基金：
中国国家自然科学基金;
关键词：
Tetrahydro-beta-carboline; Hydroxamate; HDAC inhibitors; Antitumor;
D O I：
10.1016/j.bmcl.2024.129986
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Histone deacetylases (HDACs) are validated drug targets for various therapeutic applications. A series of Tetrahydro-beta-carboline-based hydroxamate derivatives, designed as HDAC inhibitors (HDACis), were synthesized. Compound 11g exhibited strong inhibitory activity against HDAC1 and the A549 cancer cell line. Additionally, this compound increased the levels of acetylated histone H3 and H4. Notably, 11g effectively arrested A549 cells in the G2/M phase and also increased ROS production and DNA damage, thereby inducing apoptosis. Further molecular docking experiments illustrated the potential interactions between compound 11g and HDAC1. These findings suggested that the novel Tetrahydro-beta-carboline-based HDACis could serve as a promising framework for further optimization as anticancer agents.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] Synthesis and Biological Evaluation of B-Cell Lymphoma 6 Inhibitors of N-Phenyl-4-pyrimidinamine Derivatives Bearing Potent Activities against Tumor Growth
    Guo, Weikai
    Xing, Yajing
    Zhang, Qiansen
    Xie, Jiuqing
    Huang, Dongxia
    Gu, Haijun
    He, Peng
    Zhou, Miaoran
    Xu, Shifen
    Pang, Xiufeng
    Liu, Mingyao
    Yi, Zhengfang
    Chen, Yihua
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (02) : 676 - 695
  • [22] Novel β-carboline-based indole-4,7-quinone derivatives as NAD(P)H: Quinone-oxidoreductase-1 inhibitor with potent antitumor activities by inducing reactive oxygen species, apoptosis, and DNA damage
    Guo, Yibing
    Xu, Liancheng
    Ling, Changchun
    Yang, Tao
    Zheng, Wenjie
    Lv, Jin
    Guo, Qingsong
    Chen, Bohua
    CHEMICAL BIOLOGY & DRUG DESIGN, 2020, 96 (06) : 1433 - 1446
  • [23] Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study
    Li, Xiaoyang
    Zhang, Yingjie
    Jiang, Yuqi
    Wu, Jingde
    Inks, Elizabeth S.
    Chou, C. James
    Gao, Shuai
    Hou, Jinning
    Ding, Qinge
    Li, Jingyao
    Wang, Xue
    Huang, Yongxue
    Xu, Wenfang
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 134 : 185 - 206
  • [24] Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities
    Haviv, F
    Bradley, MF
    Kalvin, DM
    Schneider, AJ
    Davidson, DJ
    Majest, SM
    McKay, LM
    Haskell, CJ
    Bell, RL
    Nguyen, B
    Marsh, KC
    Surber, BW
    Uchic, JT
    Ferrero, J
    Wang, YC
    Leal, J
    Record, RD
    Hodde, J
    Badylak, SF
    Lesniewski, RR
    Henkin, J
    JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (08) : 2838 - 2846
  • [25] Synthesis, enzymatic inhibition, and cancer cell growth inhibition of novel δ-lactam-based histone deacetylase (HDAC) inhibitors
    Kim, Hwan Mook
    Lee, Kiho
    Park, Bum Woo
    Ryu, Dong Kyu
    Kim, Kangjeon
    Lee, Chang Woo
    Park, Song-Kyu
    Han, Jung Whan
    Lee, Hee Yoon
    Lee, Hyun Yong
    Han, Gyoonhee
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (15) : 4068 - 4070
  • [26] Novel potent azetidine-based inhibitors bind irreversibly to Stat3 DNA-binding domain (DBD) and are efficacious against tumor growth in mice
    Chen, Yue
    Zhai, Ning
    Zhu, Yinsong
    Yue, Peibin
    Verma, Nagendra
    Brotherton-Pleiss, Christine
    Fu, Wenzhen
    Nakamura, Kayo
    Chen, Weiliang
    Tius, Marcus
    Lopez-Tapia, Francisco J.
    Turkson, James
    CANCER RESEARCH, 2023, 83 (07)
  • [27] Novel Benzohydroxamate-Based Potent and Selective Histone Deacetylase 6 (HDAC6) Inhibitors Bearing a Pentaheterocyclic Scaffold: Design, Synthesis, and Biological Evaluation
    Vergani, Barbara
    Sandrone, Giovanni
    Marchini, Mattia
    Ripamonti, Chiara
    Cellupica, Edoardo
    Galbiati, Elisabetta
    Caprini, Gianluca
    Pavich, Gianfranco
    Porro, Giulia
    Rocchio, Ilaria
    Lattanzio, Maria
    Pezzuto, Marcello
    Skorupska, Malgorzata
    Cordella, Paola
    Pagani, Paolo
    Pozzi, Pietro
    Pomarico, Roberta
    Modena, Daniela
    Leoni, Flavio
    Perego, Raffaella
    Fossati, Gianluca
    Steinkuhler, Christian
    Stevenazzi, Andrea
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (23) : 10711 - 10739
  • [28] Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity
    Parish, CR
    Freeman, C
    Brown, KJ
    Francis, DJ
    Cowden, WB
    CANCER RESEARCH, 1999, 59 (14) : 3433 - 3441
  • [29] Novel 4-arylaminoquinazoline derivatives with (E)-propen-1-yl moiety as potent EGFR inhibitors with enhanced antiproliferative activities against tumor cells
    Chen, Li
    Zhang, Yaling
    Liu, Juan
    Wang, Weijia
    Li, Xiabing
    Zhao, Lijun
    Wang, Wei
    Li, Baolin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 138 : 689 - 697
  • [30] Novel potent HIF-1 inhibitors for the prevention of tumor metastasis: discovery and optimization of 3-aryl-5-indazole-1,2,4-oxadiazole derivatives
    Sheng, Rong
    Li, Shan
    Lin, Guanyu
    Shangguan, Shihao
    Gu, Yongchuan
    Qiu, Ni
    Cao, Ji
    He, Qiaojun
    Yang, Bo
    Hu, Yongzhou
    RSC ADVANCES, 2015, 5 (100) : 81817 - 81830
12345